: Total investment property stood at €118.0 million at year-end .
: Ongoing heavy investment in the development of obicetrapib . Finance: New Amsterdam Invest N.V. New Amsterdam
The company's full-year 2025 financial report, released in , shows a focus on clinical development . : Total investment property stood at €118
Because "New Amsterdam" refers to several popular topics, here are the most recent and relevant reports for each: New Amsterdam